Lakefront Biotherapeutics (LKFT) Work In Process (2021 - 2023)

Lakefront Biotherapeutics (LKFT) has reported Work In Process for 3 consecutive years, with $14.3 million the latest figure, recorded in Q4 2023.

• Quarterly Work In Process rose 117.54% year-over-year to $14.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $14.3 million (up 117.54% YoY) and the FY2023 annual result came in at $14.3 million, up 117.54% from the prior year.
• Work In Process rose to $14.3 million in Q4 2023 per LKFT's latest filing, from $6.6 million in the prior quarter.
• Over the last five years, Work In Process for LKFT reached as high as $14.3 million in Q4 2023 and fell as low as $1.6 million in Q4 2021.
• A 3-year average of $7.5 million and a median of $6.6 million in 2022 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2022 — Work In Process surged 320.86% — and 2023, when it jumped 117.54%.
• Year by year, Work In Process stood at $1.6 million in 2021, then surged by 320.86% to $6.6 million in 2022, then soared by 117.54% to $14.3 million in 2023.
• According to Business Quant data, Work In Process over the past three periods registered $14.3 million, $6.6 million, and $1.6 million for Q4 2023, Q4 2022, and Q4 2021 respectively.